

Makoto Tahara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1933442/publications.pdf>

Version: 2024-02-01

131
papers

14,621
citations

66343

42
h-index

20358

116
g-index

133
all docs

133
docs citations

133
times ranked

13228
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. <i>Neuro-Oncology</i> , 2022, 24, 997-1007.	1.2	72
2	Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. <i>Oncologist</i> , 2022, 27, e194-e198.	3.7	18
3	Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit. <i>Oncologist</i> , 2022, 27, 565-572.	3.7	12
4	Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. <i>Journal of Clinical Oncology</i> , 2022, 40, 2321-2332.	1.6	79
5	Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1980-1990.	1.6	74
6	Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial. <i>Cancer</i> , 2022, 128, 2281-2287.	4.1	8
7	Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. <i>Oral Oncology</i> , 2022, 128, 105815.	1.5	17
8	Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. <i>Oncologist</i> , 2022, , .	3.7	18
9	Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. <i>Cancer Research Communications</i> , 2022, 2, 739-753.	1.7	2
10	A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 199-204.	1.3	2
11	Multi-institutional Survey of Squamous Cell Carcinoma of the External Auditory Canal in Japan. <i>Laryngoscope</i> , 2021, 131, E870-E874.	2.0	15
12	Electrochemotherapy in the Treatment of Head and Neck Cancer: Current Conditions and Future Directions. <i>Cancers</i> , 2021, 13, 1418.	3.7	12
13	Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. <i>European Journal of Cancer</i> , 2021, 147, 51-57.	2.8	26
14	Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 450-462.	10.7	287
15	Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial. <i>Oral Oncology</i> , 2021, 115, 105192.	1.5	22
16	Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib. <i>Thyroid</i> , 2021, 31, 1226-1234.	4.5	24
17	A phase II study of chemoselection with docetaxel, cisplatin, and 5-fluorouracil as a strategy for organ preservation in patients with resectable esophageal cancer (CROC trial).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4027-4027.	1.6	12
18	Planned drug holiday in a cohort study exploring the effect of lenvatinib on differentiated thyroid cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6070-6070.	1.6	5

#	ARTICLE	IF	CITATIONS
19	Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3108-3108.	1.6	19
20	Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1619-1627.	2.2	6
21	RARE-07. EFFICACY AND SAFETY OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. <i>Neuro-Oncology</i> , 2021, 23, i42-i42.	1.2	0
22	A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1812-1821.	2.2	43
23	MO3-4 Impact of baseline tumor size on overall survival in patients with RR-DTC treated with lenvatinib (SELECT). <i>Annals of Oncology</i> , 2021, 32, S296.	1.2	2
24	P-94 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009. <i>Oral Oncology</i> , 2021, 118, 10-11.	1.5	1
25	Sites of invasion of cancer of the external auditory canal predicting oncologic outcomes. <i>Head and Neck</i> , 2021, 43, 3097-3105.	2.0	7
26	SY33-3 Novel drugs for anaplastic thyroid cancer. <i>Annals of Oncology</i> , 2021, 32, S274.	1.2	0
27	MO8-5 Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer. <i>Annals of Oncology</i> , 2021, 32, S300.	1.2	1
28	Cholangioscopic finding of severe hemorrhagic cholangitis associated with immune-related adverse events. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 859-860.	1.0	1
29	Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 173-179.	1.3	15
30	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition – A Descriptive Observational Retrospective Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 765608.	2.8	10
31	Management of VEGFR-Targeted TKI for Thyroid Cancer. <i>Cancers</i> , 2021, 13, 5536.	3.7	14
32	Comparison of salvage surgery for recurrent or residual head and neck squamous cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 288-295.	1.3	21
33	Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan. <i>Advances in Therapy</i> , 2020, 37, 3850-3862.	2.9	23
34	Salvage Reconstructive Surgery During Nivolumab Therapy for a Patient With Hypopharyngeal Cancer. <i>Clinical Medicine Insights: Case Reports</i> , 2020, 13, 117954762090885.	0.7	3
35	Immunotherapy for squamous cell carcinoma of the head and neck. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1089-1096.	1.3	39
36	Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 571304.	2.8	10

#	ARTICLE	IF	CITATIONS
37	Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. <i>Future Oncology</i> , 2020, 16, 1235-1243.	2.4	36
38	De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies. <i>Journal of Clinical Oncology</i> , 2020, 38, 2552-2557.	1.6	58
39	Impact of outpatient pharmacy interventions on management of thyroid patients receiving lenvatinib. <i>SAGE Open Medicine</i> , 2020, 8, 205031212093090.	1.8	11
40	Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141). <i>Head and Neck</i> , 2020, 42, 2852-2862.	2.0	26
41	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. <i>Lancet Oncology</i> , The, 2020, 21, 531-540.	10.7	608
42	A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck. <i>Cancer Medicine</i> , 2020, 9, 1671-1682.	2.8	19
43	Grade 3 infusion-related reaction because of cetuximab administered with 5-fluorouracil and cisplatin chemotherapy for a recurrent and metastatic head and neck cancer patient who received chlorpheniramine 5 mg, dexamethasone 13.2 mg, and aprepitant 125 mg premedication. <i>European Journal of Oncology Pharmacy</i> , 2020, 3, e21.	0.9	1
44	Drug cost savings resulting from the outpatient pharmacy services collaborating with oncologists at outpatient clinics. <i>European Journal of Oncology Pharmacy</i> , 2020, 3, e22.	0.9	3
45	Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. <i>Annals of Oncology</i> , 2020, 31, 942-950.	1.2	240
46	Efficacy and safety of accelerated fractionated radiotherapy without elective nodal irradiation for T3N0 glottic cancer without vocal cord fixation. <i>Head and Neck</i> , 2020, 42, 1775-1782.	2.0	4
47	CTNI-67. EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS: AN EXPANDED DATASET. <i>Neuro-Oncology</i> , 2020, 22, ii58-ii58.	1.2	2
48	Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score ≥ 1, 1-19, and ≥ 20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis. <i>Cancer Research</i> , 2020, 80, LB-258-LB-258.	0.9	10
49	Activity and safety of larotrectinib in adult patients with TRK fusion cancer: An expanded data set.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3610-3610.	1.6	11
50	Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008).. <i>Journal of Clinical Oncology</i> , 2020, 38, 6502-6502.	1.6	47
51	KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 6505-6505.	1.6	21
52	Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS6589-TPS6589.	1.6	11
53	Re-challenge of Platinum-based Chemotherapy for Platinum-refractory Patients with Recurrent or Metastatic Head and Neck Cancer: Claims Data Analysis in Japan. <i>Journal of Health Economics and Outcomes Research</i> , 2020, 7, 43-51.	1.2	8
54	Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6530-6530.	1.6	4

#	ARTICLE	IF	CITATIONS
55	EPCT-08. ACTIVITY OF LAROTRECTINIB IN PEDIATRIC TROPOMYOSIN RECEPTOR KINASE (TRK) FLUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. <i>Neuro-Oncology</i> , 2020, 22, iii305-iii305.	1.2	0
56	351â€¦Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009. , 2020, , .		0
57	The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions. <i>Frontiers in Oncology</i> , 2019, 9, 668.	2.8	33
58	Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. <i>Clinical Cancer Research</i> , 2019, 25, 5221-5230.	7.0	115
59	Nivolumab treatment beyond RECISTâ€defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. <i>Cancer</i> , 2019, 125, 3208-3218.	4.1	64
60	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 1915-1928.	13.7	1,804
61	Nutritional support dependence after curative chemoradiotherapy in head and neck cancer: supplementary analysis of a phase II trial (JCOG0706S1). <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 1009-1015.	1.3	1
62	Palbociclib (PAL) + cetuximab (CET) vs CET in patients (pts) with head and neck cancer: Asian subgroup analysis. <i>Annals of Oncology</i> , 2019, 30, vi103.	1.2	0
63	Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. <i>Oral Oncology</i> , 2019, 97, 82-91.	1.5	3
64	A review of head and neck cancer staging system in the TNM classification of malignant tumors (eighth edition). <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 589-595.	1.3	19
65	A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEX) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study). <i>Frontiers in Oncology</i> , 2019, 9, 6.	2.8	9
66	Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer. <i>International Journal of Clinical Oncology</i> , 2019, 24, 789-797.	2.2	12
67	Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 86.	2.8	71
68	Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. <i>European Journal of Cancer</i> , 2019, 106, 61-68.	2.8	64
69	A Phase II study of the safety and efficacy ofâ€lenvatinib in patients with advanced thyroidâ€cancer. <i>Future Oncology</i> , 2019, 15, 717-726.	2.4	104
70	Clinical impact of cachexia in unresectable locally advanced head and neck cancer: supplementary analysis of a phase II trial (JCOG0706-S2). <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 37-41.	1.3	14
71	Pembrolizumab in Asiaâ€Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from <sc>KEYNOTE</sc>â€12. <i>Cancer Science</i> , 2018, 109, 771-776.	3.9	48
72	Treatmentâ€emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). <i>Cancer</i> , 2018, 124, 2365-2372.	4.1	77

#	ARTICLE	IF	CITATIONS
73	Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. <i>Oral Oncology</i> , 2018, 81, 45-51.	1.5	589
74	Management of recurrent or metastatic thyroid cancer. <i>ESMO Open</i> , 2018, 3, e000359.	4.5	22
75	Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , 2018, 8, 616.	2.8	17
76	Optimal management of patients with hepatocellular carcinoma treated with lenvatinib. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1095-1105.	2.4	30
77	Cohort study exploring the effect of lenvatinib on differentiated thyroid cancer. <i>Endocrine Journal</i> , 2018, 65, 1071-1074.	1.6	4
78	Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , 2018, 8, 339.	2.8	21
79	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. <i>British Journal of Cancer</i> , 2018, 119, 153-159.	6.4	329
80	CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. <i>Oncologist</i> , 2018, 23, 1079-1082.	3.7	70
81	Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC). <i>Cancer Research</i> , 2018, 78, LB-339-LB-339.	0.9	34
82	Proton beam therapy for olfactory neuroblastoma. <i>Radiotherapy and Oncology</i> , 2017, 122, 368-372.	0.6	33
83	Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. <i>European Journal of Cancer</i> , 2017, 75, 213-221.	2.8	59
84	Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 295-305.	4.7	43
85	Pharmacokinetics of initial full and subsequent reduced doses of S-1 in patients with locally advanced head and neck cancer—effect of renal insufficiency. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 407-412.	1.3	0
86	Evaluation of community pharmacist ability to ensure the safe use of oral anticancer agents: a nationwide survey in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 413-421.	1.3	24
87	Retrospective analysis of premedication, glucocorticosteroids, and H ₁ -antihistamines for preventing infusion reactions associated with cetuximab treatment of patients with head and neck cancer. <i>Journal of International Medical Research</i> , 2017, 45, 1378-1385.	1.0	11
88	A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. <i>Oral Oncology</i> , 2017, 73, 138-146.	1.5	90
89	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1104-1115.	10.7	325
90	Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data. <i>Oncologist</i> , 2017, 22, 1056-1066.	3.7	122

#	ARTICLE	IF	CITATIONS
91	Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial. <i>Thyroid</i> , 2017, 27, 1135-1141.	4.5	37
92	Impact of clinical pharmacists collaborating with oncologists in outpatient cancer chemotherapy on cost of chemotherapy. <i>Annals of Oncology</i> , 2017, 28, ix74.	1.2	1
93	Lenvatinib for Anaplastic Thyroid Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 25.	2.8	141
94	Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , 2017, 7, 72.	2.8	122
95	Optimal use of lenvatinib in the treatment of advanced thyroid cancer. <i>Cancers of the Head & Neck</i> , 2017, 2, 7.	6.2	23
96	Anti-cancer drugs for thyroid cancer. <i>Annals of Oncology</i> , 2017, 28, ix63.	1.2	0
97	Japanese clinical guidelines for molecular targeted therapies in the treatment of thyroid cancer. <i>Annals of Oncology</i> , 2017, 28, ix16.	1.2	0
98	Gene expression profiling to predict recurrence of advanced squamous cell carcinoma of the tongue: discovery and external validation. <i>Oncotarget</i> , 2017, 8, 61786-61799.	1.8	16
99	A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 91-99.	2.3	49
100	Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. <i>Journal of Clinical Oncology</i> , 2016, 34, 3838-3845.	1.6	715
101	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2016, 375, 1856-1867.	27.0	3,845
102	Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4103-4109.	3.6	78
103	Impact of pharmacist outpatient interventions on management of Lenvatinib for thyroid cancer patients. <i>Annals of Oncology</i> , 2016, 27, vii100.	1.2	0
104	Impact of prophylactic percutaneous endoscopic gastrostomy tube placement on treatment tolerance in head and neck cancer patients treated with cetuximab plus radiation. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 825-831.	1.3	6
105	Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: Final analysis results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6088-6088.	1.6	22
106	Phase II^{II} trial of chemoradiotherapy with concurrent Sâ€1 and cisplatin for clinical stage^{II}/^{III} esophageal carcinoma (^{JCOG} 0604). <i>Cancer Science</i> , 2015, 106, 1414-1420.	3.9	28
107	Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodineâ€refractory differentiated thyroid cancer. <i>Cancer Science</i> , 2015, 106, 1714-1721.	3.9	111
108	Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 621-630.	27.0	1,526

#	ARTICLE	IF	CITATIONS
109	Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2015, 16, 583-594.	10.7	358
110	Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706). <i>Cancer Science</i> , 2015, 106, 726-733.	3.9	17
111	Randomized Phase II/III Trial of Post-operative Chemoradiotherapy Comparing 3-Weekly Cisplatin with Weekly Cisplatin in High-risk Patients with Squamous Cell Carcinoma of Head and Neck: Japan Clinical Oncology Group Study (JCOG1008). <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 770-774.	1.3	56
112	Feasibility of Cisplatin/5-Fluorouracil and Panitumumab in Japanese Patients with Squamous Cell Carcinoma of the Head and Neck. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 661-669.	1.3	3
113	Evaluation of the impact of a flowchart-type leaflet for cancer inpatients. <i>SAGE Open Medicine</i> , 2014, 2, 205031211453125.	1.8	4
114	Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. <i>Lancet Oncology, The</i> , 2013, 14, 697-710.	10.7	402
115	Phase II Study of Cetuximab Plus Concomitant Boost Radiotherapy in Japanese Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 476-482.	1.3	61
116	Platinum-based Chemotherapy Plus Cetuximab for the First-line Treatment of Japanese Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of a Phase II Trial. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 524-531.	1.3	67
117	Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2013, 104, 1455-1460.	3.9	181
118	Phase I/II trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) followed by concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4074-4074.	1.6	1
119	Impact of early radiological response evaluation on radiotherapeutic outcomes in the patients with nasal cavity and paranasal sinus malignancies. <i>Journal of Radiation Research</i> , 2012, 53, 704-709.	1.6	4
120	Phase II Feasibility Trial of Adjuvant Chemoradiotherapy with 3-weekly Cisplatin for Japanese Patients with Post-operative High-risk Squamous Cell Carcinoma of the Head and Neck. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 927-933.	1.3	57
121	A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1265-1272.	2.3	102
122	Phase I trial of chemoradiotherapy with the combination of S-1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck. <i>Cancer Science</i> , 2011, 102, 419-424.	3.9	14
123	Efficacy of Concurrent Chemoradiotherapy as a Palliative Treatment in Stage IVB Esophageal Cancer Patients with Dysphagia. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 964-972.	1.3	36
124	Systemic Chemotherapy with Cisplatin Plus 5-FU (PF) for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): Efficacy and Safety of a Lower Dose of PF (80/800) at a Single Institution in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 225-230.	1.3	9
125	Phase II Trial of Concurrent Chemoradiotherapy with S-1 Plus Cisplatin in Patients with Unresectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Japan Clinical Oncology Group Study (JCOG0706). <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 460-463.	1.3	15
126	Multicenter Phase II Study of Cetuximab Plus Irinotecan in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin and Fluoropyrimidines. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 762-769.	1.3	33

#	ARTICLE	IF	CITATIONS
127	Feasibility Study of Single Agent Cisplatin and Concurrent Radiotherapy in Japanese Patients with Squamous Cell Carcinoma of the Head and Neck: Preliminary Results. Japanese Journal of Clinical Oncology, 2007, 37, 725-729.	1.3	54
128	Clinical Impact of Criteria for Complete Response (CR) of Primary Site to Treatment of Esophageal Cancer. Japanese Journal of Clinical Oncology, 2005, 35, 316-323.	1.3	102
129	Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil. Oncology Reports, 2004, 11, 9-15.	2.6	22
130	Response to entrectinib in a malignant glioneuronal tumor with <i>ARHGGEF2</i> - <i>NTRK</i> fusion. Neuro-Oncology Advances, 0, , .	0.7	2
131	Reply to V. Noronha et al. Journal of Clinical Oncology, 0, , .	1.6	0